Overview

Healthcare policy under the Trump administrations has evolved dramatically between terms. The first term was defined by the unsuccessful effort to repeal the Affordable Care Act and the successful Operation Warp Speed vaccine development program. The second term has shifted focus toward restructuring public health institutions, revising vaccine recommendations, and installing leadership that challenges mainstream medical consensus on multiple fronts.

First Term (2017–2021)

The administration's primary healthcare goal — full repeal and replacement of the Affordable Care Act (ACA) — failed in dramatic fashion when Senator John McCain cast the deciding vote against the "skinny repeal" bill in July 2017. However, the administration successfully eliminated the ACA's individual mandate penalty through the Tax Cuts and Jobs Act, removing the financial consequence for not carrying health insurance.

On drug pricing, the administration issued executive orders aimed at reducing prescription costs, including requiring hospitals to disclose negotiated prices and allowing importation of drugs from Canada. While these measures were largely incremental, they signaled a willingness to challenge pharmaceutical industry practices.

The COVID-19 pandemic dominated the final year. Operation Warp Speed, a public-private partnership launched in 2020, facilitated the development and emergency authorization of multiple COVID-19 vaccines in under a year — an unprecedented achievement in vaccine development timelines. The administration invested over $18 billion in the program, which produced vaccines from Pfizer-BioNTech, Moderna, and Johnson & Johnson.

Second Term (2025–Present)

The second term has been marked by the appointment of Robert F. Kennedy Jr. to lead the Department of Health and Human Services (HHS). Kennedy, a prominent vaccine skeptic, has overseen significant changes to federal health policy that have generated intense controversy within the medical community.

In early 2026, HHS reduced the number of routine vaccines recommended for all children from 13 to 7, and the number of diseases targeted by the federal childhood vaccination schedule was reduced from 17 to 11. Six vaccines — rotavirus, COVID-19, influenza, hepatitis A, hepatitis B, and meningococcal — were moved from routine status to "shared clinical decision making," meaning they are no longer universally recommended but left to individual doctor-patient discussions.

The administration has also restructured the FDA and CDC, reducing their regulatory authority and workforce. These changes represent a fundamental philosophical shift in how the federal government approaches public health — moving from a prescriptive, population-level approach to one emphasizing individual choice and skepticism of institutional expertise.

What Supporters Say

Supporters argue that the healthcare establishment has become too powerful and too resistant to questioning. They contend that parents should have more autonomy over their children's medical decisions, and that the previous vaccine schedule was driven partly by pharmaceutical industry influence rather than purely by medical necessity.

Proponents of the second-term approach argue that institutions like the FDA and CDC lost public trust during the pandemic through inconsistent messaging and perceived politicization, and that reform is necessary to restore credibility. They point to Kennedy's focus on chronic disease, food safety, and environmental health as addressing neglected public health priorities.

What Critics Say

Critics warn that reducing vaccine recommendations could lead to outbreaks of preventable diseases, particularly among children. The medical establishment — including the American Medical Association, American Academy of Pediatrics, and major research universities — has overwhelmingly opposed the schedule changes, arguing they are not supported by scientific evidence and could cost lives.

Opponents argue that placing a vaccine skeptic at the head of HHS undermines decades of public health progress and sends a dangerous signal that established science is optional. They contend that the restructuring of the FDA and CDC will slow drug approvals, reduce food safety oversight, and leave the nation less prepared for future pandemics.

Key Facts & Figures

Want the full insider perspective?

Sean Spicer's Trump 2.0 provides a detailed look at the people and policies shaping this administration. With a foreword by President Trump himself, it covers the topics discussed on this page and much more.

Get the Book on Amazon(paid link)